Simplified quantification of [(18)F]FE-PE2I PET in Parkinson's disease: Discriminative power, test-retest reliability and longitudinal validity during early peak and late pseudo-equilibrium.
Simplified quantification of [(18)F]FE-PE2I PET in Parkinson's disease: Discriminative power, test-retest reliability and longitudinal validity during early peak and late pseudo-equilibrium.
复制标题
帕金森病患者[(18)F]FE-PE2I PET的简化定量：早期峰值和晚期假平衡时的辨别力、重测信度和纵向效度。
DOI：
10.1177/0271678x20958755
复制
发表时间：
2021-06
期刊：
影响因子：
--
通讯作者：
Varrone A
中科院分区：
文献类型：
--
作者：
Brumberg J;Kerstens V;Cselényi Z;Svenningsson P;Sundgren M;Fazio P;Varrone A
用[18F]FE-PE2I PET定量检测多巴胺转运体(DAT)的可用性，可以检测突触前多巴胺缺乏，并为帕金森病(PD)提供一个潜在的进展标志。简化量化是可行的，但短获取协议的时间窗口可能会对纹状体结合估计的可靠性产生实质性影响。采用横断面(33例帕金森病患者，24例对照组)、重测(9例)和纵向(12例)队列的动态[18F]FE-PE2I PET数据，以评估在假性平衡早期和晚期测量的特异性结合比(SBR)的变异性和可靠性。受试者工作特征曲线下面积(PD与对照组相比)在SBR早期(0.996)和晚期(0.991)较高。早期SBR提供了比晚期SBR更有利的效应大小、绝对变异性和测量标准误差(尾状：1.29比1.23；6.9%比9.8%；0.09比0.20；壳核：1.75比1.67；7.7%比14.0%；0.08比0.17)。两个时间窗的年百分比变化相似(−7.2%-8.5%)，但仅在SBR早期显著下降。虽然早期和晚期的[18F]FE-PE2I PET采集对区分PD患者和对照组具有相似的区分能力，但如果使用[18F]FE-PE2I测量DAT可用性的纵向变化，则可以推荐早期峰值平衡采集。
Quantification of dopamine transporter (DAT) availability with [18F]FE-PE2I PET enables the detection of presynaptic dopamine deficiency and provides a potential progression marker for Parkinson`s disease (PD). Simplified quantification is feasible, but the time window of short acquisition protocols may have a substantial impact on the reliability of striatal binding estimates. Dynamic [18F]FE-PE2I PET data of cross-sectional (33 PD patients, 24 controls), test–retest (9 patients), and longitudinal (12 patients) cohorts were used to assess the variability and reliability of specific binding ratios (SBR) measured during early peak and late pseudo-equilibrium. Receiver operating characteristics area under the curve (PD vs. controls) was high for early (0.996) and late (0.991) SBR. Early SBR provided more favourable effect size, absolute variability, and standard error of measurement than late SBR (caudate: 1.29 vs. 1.23; 6.9% vs. 9.8%; 0.09 vs. 0.20; putamen: 1.75 vs. 1.67; 7.7% vs. 14.0%; 0.08 vs. 0.17). The annual percentage change was comparable for both time windows (−7.2%–8.5%), but decline was significant only for early SBR. Whereas early and late [18F]FE-PE2I PET acquisitions have similar discriminative power to separate PD patients and controls, the early peak equilibrium acquisition can be recommended if [18F]FE-PE2I is used to measure longitudinal changes of DAT availability.